Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

antibody-conjugated drug

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Antibody-Drug Conjugates (ADCs) (5) Drug Intermediate (1) Drug-Linker Conjugates for ADC (3) ADC Antibody (2) ADC Payload (3) Ephrin Receptor (1) Epigenetic Reader Domain (1) Isotope-Labeled Compounds (2) Microtubule/Tubulin (5) Nectin-4 (2) PD-1/PD-L1 (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (1) SARS-CoV (1) Topoisomerase (2) Transmembrane Glycoprotein (2)
By Research Areas:	Cancer (14) Infection (1)

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: Drug Intermediate Drug Isomer Drug Derivative Drug Metabolite Antibody-Drug Conjugates (ADCs) Peptide-Drug Conjugates (PDCs) Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC ADC Linker

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19792

Mertansine Maximum Cited Publications 27 Publications Verification DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Payload	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-153360

MC-GGFG-AM-(10Me-11F-Camptothecin)	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .

HY-171821

PF-08046054 SGN-PDL1V	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent **antibody-drug conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated* to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P991501

Meplazumab HcHAb18	ADC Antibody Transmembrane Glycoprotein SARS-CoV	Infection Cancer
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .

HY-P990627

Anti-EphA2 Antibody (1C1) MEDI-547 antibody	ADC Antibody Ephrin Receptor	Cancer
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .

HY-13631F

Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research .

HY-164995

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .

HY-145767A

SN-38-CO-DMEDA TFA	Drug Intermediate	Others
SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035 .

HY-180467

Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me	ADC Linker	Cancer
Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me (Compound G12) is a disaccharide linker. Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me can be efficiently recognized by the endo-glycosidase Endo-S2 and can be directedly transferred to the conserved N-glycosylation site (Asn297 position) of the antibody's Fc domain through enzymatic catalytic reactions, thereby achieving site-specific modification of the antibody. Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me can be used for for the synthesis of antibody-conjugated drugs (ADCs) .

HY-183939

L1-CIDE-BRM1-13	PROTAC-Linker Conjugates for PAC	Others
L1-CIDE-BRM1-13 (Compound 15) is a linker-drug precursor moiety formed by the covalent conjugation of a PROTAC degrader with a linker for degrader-antibody conjugates (DACs). L1-CIDE-BRM1-13 can be used for the synthesis of DACs .

HY-19792S2

Mertansine-d3 DM1-d₃; Maytansinoid DM1-d₃	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-19792S

Mertansine-13C,d3 DM1-¹³C,d₃; Maytansinoid DM1-¹³C,d₃	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-185483

AMG-172	Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Microtubule/Tubulin	Cancer
AMG-172 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonal anti-CD27L antibody conjugated to DM1 (HY-19792) via the non-cleavable linker MCC. AMG-172 releases the intracellular active component Lysine-MCC-DM through catabolism. Lysine-MCC-DM inhibits the assembly and disassembly dynamics of Microtubule and induces cell arrest at metaphase. AMG-172 can be used for research on relapsed/refractory clear cell renal cell carcinoma .

Cat. No.	Product Name	Type

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Fluorescent Dyes
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

Enfortumab vedotin-ejfv (solution)

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv 1 Publications Verification	Fluorescent Dyes
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

Enfortumab vedotin-ejfv

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-171821

PF-08046054 SGN-PDL1V	Fluorescent Dyes
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

Cat. No.	Product Name	Target	Research Area	Image

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent **antibody-drug conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated* to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P991501

Meplazumab HcHAb18	ADC Antibody Transmembrane Glycoprotein SARS-CoV	Infection Cancer
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .

HY-P990627

Anti-EphA2 Antibody (1C1) MEDI-547 antibody	ADC Antibody Ephrin Receptor	Cancer
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .

Cat. No.	Product Name	Chemical Structure

HY-19792S2

Mertansine-d3
Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

Mertansine-d3

Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-19792S

Mertansine-13C,d3
Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

Mertansine-13C,d3

Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.